This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Mar 1;20(5):1158-60.

doi: 10.1200/JCO.2002.20.5.1158.

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

Stephen A Cannistra

PMID: 11870154
DOI: 10.1200/JCO.2002.20.5.1158

Editorial

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

Stephen A Cannistra. J Clin Oncol. 2002.

. 2002 Mar 1;20(5):1158-60.

doi: 10.1200/JCO.2002.20.5.1158.

Author

Stephen A Cannistra

PMID: 11870154
DOI: 10.1200/JCO.2002.20.5.1158

No abstract available

PubMed Disclaimer

Comment on

Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N. Cantù MG, et al. J Clin Oncol. 2002 Mar 1;20(5):1232-7. doi: 10.1200/JCO.2002.20.5.1232. J Clin Oncol. 2002. PMID: 11870165 Clinical Trial.

Similar articles

Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
Colombo N. Colombo N. Future Oncol. 2013 Dec;9(12 Suppl):19-23. doi: 10.2217/fon.13.206. Future Oncol. 2013. PMID: 24195526 Review.
Treatment options in patients with recurrent ovarian cancer.
Gadducci A, Conte P, Cianci C, Negri S, Genazzani AR. Gadducci A, et al. Anticancer Res. 2001 Sep-Oct;21(5):3557-64. Anticancer Res. 2001. PMID: 11848523 Review.
Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Colombo N, et al. Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review.
Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
Lowery WJ, Lowery AW, Barnett JC, Lopez-Acevedo M, Lee PS, Secord AA, Havrilesky L. Lowery WJ, et al. Gynecol Oncol. 2013 Sep;130(3):426-30. doi: 10.1016/j.ygyno.2013.06.011. Epub 2013 Jun 14. Gynecol Oncol. 2013. PMID: 23769759
Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K. Markman M, et al. Gynecol Oncol. 2000 Apr;77(1):112-5. doi: 10.1006/gyno.2000.5755. Gynecol Oncol. 2000. PMID: 10739699 Clinical Trial.

See all similar articles

Cited by

Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.
Eskander RN, Tewari KS. Eskander RN, et al. Clin Pharmacol. 2013 Oct 3;5(Suppl 1):55-61. doi: 10.2147/CPAA.S45885. Clin Pharmacol. 2013. PMID: 24124397 Free PMC article. Review.
Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients.
Ma MC, Lavi ES, Altwerger G, Lin ZP, Ratner ES. Ma MC, et al. PLoS One. 2024 Jul 8;19(7):e0305273. doi: 10.1371/journal.pone.0305273. eCollection 2024. PLoS One. 2024. PMID: 38976671 Free PMC article.
Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial.
Rothermundt C, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T, Kaye S, Gore M. Rothermundt C, et al. Br J Cancer. 2006 Jan 16;94(1):74-8. doi: 10.1038/sj.bjc.6602879. Br J Cancer. 2006. PMID: 16306873 Free PMC article. Clinical Trial.
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES. Whicker ME, et al. BMC Cancer. 2016 Jul 27;16:550. doi: 10.1186/s12885-016-2598-1. BMC Cancer. 2016. PMID: 27465688 Free PMC article.
The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.
Zhang Y, Mei Q, Liu Y, Li X, Brock MV, Chen M, Dong L, Shi L, Wang Y, Guo M, Nie J, Han W. Zhang Y, et al. Oncoimmunology. 2017 May 17;6(9):e1323619. doi: 10.1080/2162402X.2017.1323619. eCollection 2017. Oncoimmunology. 2017. PMID: 28932630 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information